Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy

Study Overview
=================
Brief Summary
-----------------
The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components. Elements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of pro-inflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation-induced thrombosis. Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. Very few data are available regarding the biological disorders of coagulation in these patients. Th purpose of this project is to analyze hemostasis and coagulation of patients with infection of COVID-19 and severe pneumonia.

Official Title
-----------------
Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy

Conditions
-----------------
COVID-19, Pneumonia, ARDS, Hemostasis, Coagulation

Intervention / Treatment
-----------------
* Other: venous ultrasound
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients hospitalized in medical ICU with pneumonia due to COVID-19 infection Exclusion Criteria: patients< 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge|
|Other: blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation of thrombin time (in secondes) in Covid-19 patients with pneumonia admitted in ICU. | The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds) | up to 6 weeks | 
| Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. | Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | 
| Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. | Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | 
| Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU. | Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, pneumonia, ARDS, venous ultrasound, hemostasis, coagulation